Highest-materiality recent filing
Chain Bridge I shareholders approve extension to Nov 2026; 393K shares redeemed for ~$4.72M
Shareholders approved amendment extending deadline for initial business combination from Nov 15, 2025 to Nov 15, 2026.
Chain Bridge I extends SPAC deadline to Nov 2026 via monthly trust contributions from Fulton AC
Fulton AC to contribute $0.01 per non-redeemed public share monthly starting Nov 16, 2025.
Chain Bridge I and CommLoan sign LOI for $50M pre-money business combination; expects Nasdaq listing
Non-binding LOI between SPAC Chain Bridge I (CBRRF) and CommLoan, a commercial real estate lending tech company.
Chain Bridge I terminates auditor Frank Rimerman after $200K error, material weakness
Audit Committee terminated Frank, Rimerman effective April 4, 2025; engaged RBSM as new auditor.
Chain Bridge I terminates Phytanix Bio merger agreement; appoints RBSM as new auditor
Mutual termination of Business Combination Agreement with Phytanix Bio effective April 7, 2025.
Audit Committee determined unaudited Q3 2024 interim financial statements cannot be relied upon due to error.
Chain Bridge I delisted from Nasdaq; shareholders approve extension, 550K shares redeemed
Nasdaq will suspend trading of CBRG shares and units on Nov 19; shares to trade on OTCQB under symbol CBRRF.
Nasdaq delisting notice received Nov 12; trading suspension effective at open on Nov 19, 2024.
Nasdaq to delist Chain Bridge I; company signs non-redemption agreements to retain trust funds
Nasdaq notified Chain Bridge I on Nov 11 it will deliver delisting letter on Nov 12 because it missed the 36-month deadline to complete a business combination.
Chain Bridge I to merge with Phytanix Bio at $58M equity value, ticker to become PHYX
Business Combination Agreement signed July 22, 2024; closing expected Q4 2024.
Phytanix Bio agreed to loan Chain Bridge I $1,590,995.12 on June 26, 2024 via unsecured non-interest bearing promissory note.
Chain Bridge I receives Nasdaq deficiency notice for failing 300 public holders minimum
Notice on June 20, 2024 for non-compliance with Nasdaq Listing Rule 5550(a)(3) requiring minimum 300 public holders.
Chain Bridge I shareholders approve extension to Nov 15, 2024; ~$34.5M redeemed
Shareholders approved extending business combination deadline from Feb 15, 2024 to Nov 15, 2024.
Buyer acquired 3,035,000 Class B shares and warrants for 7,385,000 Class A shares in private placement.
Chain Bridge I sells sponsor shares and warrants; board and CEO to resign
Buyer to acquire 3,035,000 Class B shares and warrants for 7,385,000 Class A shares from Sponsor and CB Co-Investment.
Chain Bridge I to redeem public shares at ~$10.80/share, liquidate by Nov 15, 2023
Trust account balance ~$44.9M as of Oct 30, 2023; redemption price ~$10.80 per public share.
Chain Bridge I shareholders approve extension to November 15, 2023 for business combination
Extension approved with 22.37M votes for, 1.30M against, 0.48M abstain.
Chain Bridge I enters non-redemption agreements to reduce redemptions ahead of extension vote
Sponsor and CB Co-Investment agree to transfer up to 150,000 founder shares per third party in exchange for not redeeming 400,000 public shares at May 12 special meeting.
Chain Bridge I sets record date April 4, trust value $10.44, enters LOI with merger target
Extraordinary general meeting on May 5, 2023 to vote on extension proposal for SPAC deadline.
Chain Bridge I completes $230M IPO, places $234.6M in trust for SPAC merger
IPO of 23M units at $10/unit, including 3M overallotment; gross proceeds $230M.
Andrew Kucharchuk, age 43, succeeded Mr. Lazarus as the Company’s Chief Financial Officer, effective April 1, 2024.
On April 1, 2024, Roger Lazarus, the Chief Financial Officer of Chain Bridge I (the “Company”), notified the board of directors of the Company (the “Board”) of his resignation, effective immediately.
On February 21, 2024, the Board of Directors (the “Board”) of Chain Bridge I (the “Company”) appointed Oliver Wiener as a director.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
appointed Andrew Cohen as Chief Executive Officer of the Company.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
Prior to resigning, the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by such resignations and appointed Andrew Cohen as Chief Executive Officer of the Company.
Max materiality 1.00 · Median 0.55 · Most common event other_material